Intracerebroventricular Administration of a 2′-O-Methyl Phosphorothioate Antisense Oligonucleotide Results in Activation of the Innate Immune System in Mouse Brain
Restricted accessResearch articleFirst published online April, 2018
Intracerebroventricular Administration of a 2′-O-Methyl Phosphorothioate Antisense Oligonucleotide Results in Activation of the Innate Immune System in Mouse Brain
Antisense oligonucleotides (AONs) are versatile molecules that can be used to modulate gene expression by binding to RNA. The therapeutic potential of AONs appears particularly high in the central nervous system, due to excellent distribution and uptake in brain cells, as well as good tolerability in clinical trials thus far. Nonetheless, immune stimulation in response to AON treatment in the brain remains a concern. For this reason we performed RNA sequencing analysis of brain tissue from mice treated intracerebroventricularly with phosphorothioate, 2′-O-methyl modified AONs. A significant upregulation of immune system associated genes was observed in brains of AON treated mice, with the striatum showing largest transcriptional changes. Strongest upregulation was seen for the antiviral enzyme 2′-5′-oligoadenylate synthase-like protein 2 (Oasl2) and Bone marrow stromal antigen 2 (Bst2). Histological analysis confirmed activation of microglia and astrocytes in striatum. The upregulation of immune system associated genes was detectable for at least 2 months after the last AON administration, consistent with a continuous immune response to the AON.
Get full access to this article
View all access options for this article.
References
1.
LundinKE, GissbergO and SmithCI. (2015). Oligonucleotide therapies: the past and the present. Human Gene Ther, 26:475–485.
2.
KhvorovaA and WattsJK. (2017). The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol, 35:238–248.
3.
EversMM, ToonenLJ and van Roon-MomWM. (2015). Antisense oligonucleotides in therapy for neurodegenerative disorders. Adv Drug Deliv Rev, 87:90–103.
4.
Casaca-CarreiraJ, TemelY, LarrakoetxeaI and JahanshahiA. (2017). Distribution and penetration of intracerebroventricularly administered 2′OMePS oligonucleotide in the mouse brain. Nucleic Acid Ther, 27:4–10.
5.
Juliano RL. (2016). The delivery of therapeutic oligonucleotides. Nucleic Acids Res, 44:6518–6548.
6.
RigoF, ChunSJ, NorrisDA, HungG, LeeS, MatsonJ, FeyRA, GausH, HuaY, et al. (2014). Pharmacology of a central nervous system delivered 2′-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates. J Pharmacol Exp Ther, 350:46–55.
7.
Chiriboga CA. (2017). Nusinersen for the treatment of spinal muscular atrophy. Expert Rev Neurother, 17:955–962.
8.
HuaY, SahashiK, HungG, RigoF, PassiniMA, BennettCF and KrainerAR. (2010). Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev, 24:1634–1644.
9.
KordasiewiczHB, StanekLM, WancewiczEV, MazurC, McAlonisMM, PytelKA, ArtatesJW, WeissA, ChengSH, et al. (2012). Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron, 74:1031–1044.
MillerTM, PestronkA, DavidW, RothsteinJ, SimpsonE, AppelSH, AndresPL, MahoneyK, AllredP, et al. (2013). An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol, 12:435–442.
12.
SharmaVK, SharmaRK and SinghSK. (2014). Antisense oligonucleotides: modifications and clinical trials. MedChemComm, 5:1454–1471.
13.
Levin AA. (1999). A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta, 1489:69–84.
14.
BrownDA, KangSH, GryaznovSM, DeDionisioL, HeidenreichO, SullivanS, XuX and NerenbergMI. (1994). Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem, 269:26801–26805.
15.
GuvakovaMA, YakubovLA, VlodavskyI, TonkinsonJL and SteinCA. (1995). Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem, 270:2620–2627.
16.
GalbraithWM, HobsonWC, GiclasPC, SchechterPJ and AgrawalS. (1994). Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev, 4:201–206.
17.
BjersingJL, ErikssonK, TarkowskiA, and CollinsLV. (2004). The arthritogenic and immunostimulatory properties of phosphorothioate oligodeoxynucleotides rely on synergy between the activities of the nuclease-resistant backbone and CpG motifs. Inflammation, 28:39–51.
18.
ElepfandtP, RupprechtS, Schoning-BurkhardtB, VolkHD and WoiciechowskyC. (2002). Oligodeoxynucleotides induce brain inflammation in rats when infused intracerebroventricularly. Neurosci Lett, 322:107–110.
19.
MengW, YamazakiT, NishidaY and Hanagata.N (2011). Nuclease-resistant immunostimulatory phosphodiester CpG oligodeoxynucleotides as human Toll-like receptor 9 agonists. BMC Biotechnol, 11:88.
MonteithDK, HenrySP, HowardRB, FlournoyS, LevinAA, BennettCF and CrookeST. (1997). Immune stimulation—a class effect of phosphorothioate oligodeoxynucleotides in rodents. Anticancer Drug Des, 12:421–432.
22.
ZhaoQ, TemsamaniJ, IadarolaPL, JiangZ and AgrawalS. (1996). Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem Pharmacol, 51:173–182.
23.
Peng HoS, LivanovV, ZhangW, LiJ and LesherT. (1998). Modification of phosphorothioate oligonucleotides yields potent analogs with minimal toxicity for antisense experiments in the CNS. Brain Res Mol Brain Res, 62:1–11.
24.
Casaca-CarreiraJ, ToonenLJ, EversMM, JahanshahiA, van-Roon-MomWM and TemelY. (2016). In vivo proof-of-concept of removal of the huntingtin caspase cleavage motif-encoding exon 12 approach in the YAC128 mouse model of Huntington's disease. Biomed Pharmacother, 84:93–96.
25.
EversMM, TranHD, ZalachorasI, MeijerOC, den DunnenJT, van OmmenGJ, Aartsma-RusA and van Roon-MomWM. (2014). Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification. Nucleic Acid Ther, 24:4–12.
26.
ToonenLJA, RigoF, van Attikum andH, van Roon-MomWMC. (2017). Antisense oligonucleotide-mediated removal of the polyglutamine repeat in spinocerebellar ataxia type 3 mice. Mol Ther Nucleic acids, 8:232–242.
27.
ShitakaY, TranHT, BennettRE, SanchezL, LevyMA, DikranianK and BrodyDL. (2011). Repetitive closed-skull traumatic brain injury in mice causes persistent multifocal axonal injury and microglial reactivity. J Neuropathol Exp Neurol, 70:551–567.
28.
BrownGC and NeherJJ. (2010). Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol Neurobiol, 41:242–247.
29.
VanGuilderHD, BixlerGV, BrucklacherRM, FarleyJA, YanH, WarringtonJP, SonntagWE and Freeman.WM (2011). Concurrent hippocampal induction of MHC II pathway components and glial activation with advanced aging is not correlated with cognitive impairment. J Neuroinflamm, 8:138.
30.
RobinsonMD and OshlackA. (2010). A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol, 11:R25.
31.
RobinsonMD, McCarthyDJ and SmythGK. (2010). edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics, 26:139–140.
32.
ToonenLJ, SchmidtI, LuijsterburgMS, van AttikumH and van Roon-MomWM. (2016). Antisense oligonucleotide-mediated exon skipping as a strategy to reduce proteolytic cleavage of ataxin-3. Sci Rep, 6:35200.
33.
GoelzMF, MahlerJ, HarryJ, MyersP, ClarkJ, ThigpenJE and ForsytheDB. (1998). Neuropathologic findings associated with seizures in FVB mice. Lab Anim Sci, 48:34–37.
34.
AltschulSF, GishW, MillerW, MyersEW and LipmanDJ. (1990). Basic local alignment search tool. J Mol Biol, 215:403–410.
35.
EskildsenS, JustesenJ, SchierupMH and HartmannR. (2003). Characterization of the 2′-5′-oligoadenylate synthetase ubiquitin-like family. Nucleic Acids Res, 31:3166–3173.
36.
JustesenJ, HartmannR and KjeldgaardNO. (2000). Gene structure and function of the 2′-5′-oligoadenylate synthetase family. Cell Mol Life Sci, 57:1593–1612.
37.
KramerA, GreenJ, PollardJJr., and TugendreichS. (2014). Causal analysis approaches in ingenuity pathway analysis. Bioinformatics, 30:523–530.
38.
Huang daW, ShermanBT and LempickiRA. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc, 4:44–57.
39.
PrinzM and PrillerJ. (2014). Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat Rev Neurosci, 15:300–312.
40.
FilianoAJ, GadaniSP, and KipnisJ. (2015). Interactions of innate and adaptive immunity in brain development and function. Brain Res, 1617:18–27.
CarpentierPA, BegolkaWS, OlsonJK, ElhofyA, KarpusWJ and MillerSD. (2005). Differential activation of astrocytes by innate and adaptive immune stimuli. Glia, 49:360–374.
43.
HolEM and PeknyM. (2015). Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. Curr Opin Cell Biol, 32:121–130.
44.
Aartsma-RusA. (2017). FDA approval of nusinersen for spinal muscular atrophy makes 2016 the year of splice modulating oligonucleotides. Nucleic Acid Ther, 27:67–69.
45.
DalpkeAH, ZimmermannS, AlbrechtI and HeegK. (2002). Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo. Immunology, 106:102–112.
46.
BurelSA, MachemerT, RagoneFL, KatoH, CauntayP, GreenleeS, SalimA, GaardeWA, HungG, et al. (2012). Unique O-methoxyethyl ribose-DNA chimeric oligonucleotide induces an atypical melanoma differentiation-associated gene 5-dependent induction of type I interferon response. J Pharmacol Exp Ther, 342:150–162.
47.
KakutaS, ShibataS and IwakuraY. (2002). Genomic structure of the mouse 2′,5′-oligoadenylate synthetase gene family. J Interferon Cytokine Res, 22:981–993.
48.
ChebathJ, BenechP, RevelM and VigneronM. (1987). Constitutive expression of (2′–5′) oligo A synthetase confers resistance to picornavirus infection. Nature, 330:587–588.
49.
Silverman RH. (2007). Viral encounters with 2′,5′-oligoadenylate synthetase and RNase L during the interferon antiviral response. J Virol, 81:12720–12729.
50.
TokarevA, SkaskoM, FitzpatrickK and GuatelliJ. (2009). Antiviral activity of the interferon-induced cellular protein BST-2/tetherin. AIDS Res Hum Retroviruses, 25:1197–1210.
51.
NeilSJ, ZangT and BieniaszPD. (2008). Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature, 451:425–430.
52.
GalãoRP, Le TortorecA, PickeringS, KueckT and NeilSJ. (2012). Innate sensing of HIV-1 assembly by tetherin induces NFκB-dependent proinflammatory responses. Cell Host Microbe, 12:633–644.
53.
MatsumotoM, KikkawaS, KohaseM, MiyakeK and SeyaT. (2002). Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem Biophys Res Commun, 293:1364–1369.
54.
BonowRH, AidS, ZhangY, BeckerKG and BosettiF. (2009). The brain expression of genes involved in inflammatory response, the ribosome, and learning and memory is altered by centrally injected lipopolysaccharide in mice. Pharmacogenomics J, 9:116–126.
55.
SchmeisserH, MejidoJ, BalinskyCA, MorrowAN, ClarkCR, ZhaoT, and ZoonKC. (2010). Identification of alpha interferon-induced genes associated with antiviral activity in Daudi cells and characterization of IFIT3 as a novel antiviral gene. J Virol, 84:10671–10680.
56.
ZhouX, MichalJJ, ZhangL, DingB, LunneyJK, LiuB and JiangZ. (2013). Interferon induced IFIT family genes in host antiviral defense. Int J Biol Sci, 9:200–208.
57.
DiamondMS and FarzanM. (2013). The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat Rev Immunol, 13:46–57.
58.
PeknyM, WilhelmssonU and PeknaM. (2014). The dual role of astrocyte activation and reactive gliosis. Neurosci Lett, 565:30–38.
59.
LiddelowSA, GuttenplanKA, ClarkeLE, BennettFC, BohlenCJ, SchirmerL, BennettML, MünchAE, ChungW-S, et al. (2017). Neurotoxic reactive astrocytes are induced by activated microglia. Nature, 541:481–487.
60.
DalpkeA and HelmM. (2012). RNA mediated Toll-like receptor stimulation in health and disease. RNA Biol, 9:828–842.
61.
RobbinsM, JudgeA, LiangL, McClintockK, YaworskiE and MacLachlanI. (2007). 2′-O-methyl-modified RNAs act as TLR7 antagonists. Mol Ther, 15:1663–1669.
62.
SioudM, FursetG and CekaiteL. (2007). Suppression of immunostimulatory siRNA-driven innate immune activation by 2′-modified RNAs. Biochem Biophys Res Commun, 361:122–126.
63.
SennJJ, BurelS and HenrySP. (2005). Non-CpG-containing antisense 2′-methoxyethyl oligonucleotides activate a proinflammatory response independent of Toll-like receptor 9 or myeloid differentiation factor 88. J Pharmacol Exp Ther, 314:972–979.
64.
DieboldSS, KaishoT, HemmiH, AkiraS and Reis e SousaC. (2004). Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science, 303:1529–1531.
65.
XagorariA and ChlichliaK. (2008). Toll-like receptors and viruses: induction of innate antiviral immune responses. Open Microbiol J, 2:49–59.
66.
ButchiNB, PourciauS, DuM, MorganTW and PetersonKE. (2008). Analysis of the neuroinflammatory response to TLR7 stimulation in the brain: comparison of multiple TLR7 and/or TLR8 agonists. J Immunol, 180:7604–7612.
67.
OlsonJK and MillerSD. (2004). Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol, 173:3916–3924.
68.
BowmanCC, RasleyA, TranguchSL and MarriottI. (2003). Cultured astrocytes express toll-like receptors for bacterial products. Glia, 43:281–291.
69.
LafonM, MegretF, LafageM and PrehaudC. (2006). The innate immune facet of brain: human neurons express TLR-3 and sense viral dsRNA. J Mol Neurosci, 29:185–194.
70.
MaY, HaynesRL, SidmanRL and VartanianT. (2007). TLR8: an innate immune receptor in brain, neurons and axons. Cell Cycle, 6:2859–2868.
71.
BryantCE and MonieTP. (2012). Mice, men and the relatives: cross-species studies underpin innate immunity. Open Biol, 2:120015.
72.
KetloyC, EngeringA, SrichairatanakulU, LimsalakpetchA, YongvanitchitK, PichyangkulS and RuxrungthamK. (2008). Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates. Vet Immunol Immunopathol, 125:18–30.
73.
CampbellJD, ChoY, FosterML, KanzlerH, KachuraMA, LumJA, RatcliffeMJ, SatheA, LeishmanAJ, et al. (2009). CpG-containing immunostimulatory DNA sequences elicit TNF-alpha-dependent toxicity in rodents but not in humans. J Clin Invest, 119:2564–2576.
74.
WeberC, MullerC, PodszuweitA, MontinoC, VollmerJ and ForsbachA. (2012). Toll-like receptor (TLR) 3 immune modulation by unformulated small interfering RNA or DNA and the role of CD14 (in TLR-mediated effects). Immunology, 136:64–77.
75.
ShenL, Frazer-AbelA, ReynoldsPR, GiclasPC, ChappellA, PangburnMK, YounisH and HenrySP. (2014). Mechanistic understanding for the greater sensitivity of monkeys to antisense oligonucleotide-mediated complement activation compared with humans. J Pharmacol Exp Ther, 351:709–717.
76.
HenrySP, JagelsMA, HugliTE, ManaliliS, GearyRS, GiclasPC and LevinAA. (2014). Mechanism of alternative complement pathway dysregulation by a phosphorothioate oligonucleotide in monkey and human serum. Nucleic Acid Ther, 24:326–335.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
